相关实验视频
Updated: Jul 21, 2025

12:03
Fertility Preservation in Patients with Severe Ovarian Dysfunction
Published on: March 25, 2021
4.6K
在经过体外受精的血栓友好症妇女的低分子量肝素预防性治疗
José Roberto Lambert1,2, Joji Ueno3, César Eduardo Fernandes1
1Faculdade de Medicina do ABC, Santo Andre, Brazil.
概括
低分子量肝素 (LMWH) 在经过体外受精 (IVF) 的血栓友爱症妇女中显著改善了怀孕和活产率. 用LMWH治疗还可以降低这些患者的早期怀孕丧失和堕胎率.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 血栓友爱研究 血栓友爱研究
- 辅助生殖技术 辅助生殖技术
背景情况:
- 血栓友与辅助生殖中不良妊娠结果有关.
- 低分子量肝素 (LMWH) 是一种潜在的治疗药物,用于在怀孕期间治疗血栓友症.
研究的目的:
- 调查LMWH在改善怀孕和降低试管婴儿中患有血栓友症的妇女中堕胎率方面的疗效.
- 为了比较用LMWH治疗的血栓型女性和未接受治疗的女性,以及没有血栓型女性的对照组之间的结果.
主要方法:
- 这是一项涉及104名接受试管婴儿治疗的患者的横截面研究.
- 三组:对照组 (没有血栓性),未经治疗的血栓性和用LMWH治疗的血栓性 (埃诺沙巴林).
- 标准IVF程序包括受控的卵巢过度刺激和胚胎移植;怀孕结果通过生物化学和超声波评估.
主要成果:
- 与对照组相比,未经治疗的血栓友病患者的持续怀孕和活产率明显较低.
- 未经治疗的血栓友病患者的早期怀孕丧失和堕胎率显著上升.
- 血栓友好患者的LMWH治疗使怀孕和堕胎率正常化,与对照组相似.
结论:
- 低分子量肝素 (LMWH) 对于预防被诊断患有凝血障碍的妇女进行辅助生殖而流产至关重要.
- 在接受试管婴儿的血栓友好症妇女中,LMWH治疗有效地改善了怀孕结果.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
755
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
755
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
In Vitro Fertilization
331
In vitro fertilization (IVF) is a form of assisted reproductive technology where an egg is fertilized with sperm in a controlled laboratory environment before transferring the resulting embryo into the uterus. This process is designed to help individuals and couples experiencing difficulties conceiving.
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
The IVF process begins with ovarian stimulation, during which reproductive endocrinologists prescribe hormonal medications to stimulate the ovaries to produce multiple eggs instead of the single...
331
Infertility in Females
349
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
349
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Meiosis II
183.6K
Meiosis II is the second and final stage of meiosis. It relies on the haploid cells produced during meiosis I, each of which contain only 23 chromosomes—one from each homologous initial pair. Importantly, each chromosome in these cells is composed of two joined copies, and when these cells enter meiosis II, the goal is to separate such sister chromatids using the same microtubule-based network employed in other division processes. The result of meiosis II is two haploid cells, each...
183.6K

